TeliMET NSCLC-04: A phase 2, open-label, randomized, global study of 2 telisotuzumab vedotin regimens in patients with previously treated c-Met protein–overexpressing, locally advanced/metastatic non-squamous

Authors: Alona Zer, Christine Ratajczak, Hephzibah Adamu, Shilpen Patel, Zhuangzhuang Liu, Summer Xia, Nancy Zhang

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.tps8658

Source: Full article

---

Abstract

TPS8658